JP2016518439A5 - - Google Patents

Download PDF

Info

Publication number
JP2016518439A5
JP2016518439A5 JP2016513431A JP2016513431A JP2016518439A5 JP 2016518439 A5 JP2016518439 A5 JP 2016518439A5 JP 2016513431 A JP2016513431 A JP 2016513431A JP 2016513431 A JP2016513431 A JP 2016513431A JP 2016518439 A5 JP2016518439 A5 JP 2016518439A5
Authority
JP
Japan
Prior art keywords
composition
layer
composition according
hydrocortisone
contact
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016513431A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016518439A (ja
JP6371379B2 (ja
Filing date
Publication date
Priority claimed from GBGB1308933.9A external-priority patent/GB201308933D0/en
Application filed filed Critical
Publication of JP2016518439A publication Critical patent/JP2016518439A/ja
Publication of JP2016518439A5 publication Critical patent/JP2016518439A5/ja
Application granted granted Critical
Publication of JP6371379B2 publication Critical patent/JP6371379B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016513431A 2013-05-17 2014-05-12 ヒドロコルチゾンを含有する組成物 Active JP6371379B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1308933.9 2013-05-17
GBGB1308933.9A GB201308933D0 (en) 2013-05-17 2013-05-17 Paediatric composition
PCT/GB2014/051442 WO2014184525A1 (en) 2013-05-17 2014-05-12 Composition comprising hydrocortisone

Publications (3)

Publication Number Publication Date
JP2016518439A JP2016518439A (ja) 2016-06-23
JP2016518439A5 true JP2016518439A5 (enExample) 2017-06-08
JP6371379B2 JP6371379B2 (ja) 2018-08-08

Family

ID=48746932

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016513431A Active JP6371379B2 (ja) 2013-05-17 2014-05-12 ヒドロコルチゾンを含有する組成物

Country Status (25)

Country Link
US (1) US9649280B2 (enExample)
EP (1) EP2978414B1 (enExample)
JP (1) JP6371379B2 (enExample)
KR (1) KR102219919B1 (enExample)
CN (1) CN105120848B (enExample)
AU (1) AU2014267041B2 (enExample)
BR (1) BR112015028025B1 (enExample)
CA (1) CA2909060C (enExample)
CY (1) CY1123284T1 (enExample)
DK (1) DK2978414T3 (enExample)
ES (1) ES2813382T3 (enExample)
GB (2) GB201308933D0 (enExample)
HR (1) HRP20201315T1 (enExample)
HU (1) HUE050917T2 (enExample)
IL (1) IL242275B (enExample)
LT (1) LT2978414T (enExample)
MX (1) MX379168B (enExample)
PL (1) PL2978414T3 (enExample)
PT (1) PT2978414T (enExample)
RS (1) RS60734B1 (enExample)
RU (1) RU2664678C2 (enExample)
SI (1) SI2978414T1 (enExample)
SM (1) SMT202000473T1 (enExample)
WO (1) WO2014184525A1 (enExample)
ZA (1) ZA201507210B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201119985D0 (en) 2011-11-19 2012-01-04 Diurnal Ltd Treatment of adrenal insufficiency
GB201308933D0 (en) 2013-05-17 2013-07-03 Diurnal Ltd Paediatric composition
US20190180872A1 (en) * 2017-12-12 2019-06-13 International Business Machines Corporation Second Opinion Decision Support Using Patient Electronic Medical Records
WO2025144994A1 (en) * 2023-12-29 2025-07-03 Regents Of The University Of Minnesota Compositions and methods for intranasal delivery of hydrocortisone
WO2025240605A1 (en) 2024-05-15 2025-11-20 Neurocrine Biosciences, Inc. Combination treatment

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2062634T3 (es) 1990-08-30 1994-12-16 Senju Pharma Co Composicion con liberacion controlada del farmaco.
DK0876142T3 (da) 1996-01-16 2001-11-19 Advanced Polymer Systems Inc Topisk tilførsel af lægemidler til den nedre mavetarmkanal
KR20040016202A (ko) * 2002-08-16 2004-02-21 주식회사 제이알팜 쓴맛이 차폐된 히드로코르티손 경구용 약제 조성물 및 그제조방법
JP2007533697A (ja) 2004-04-22 2007-11-22 デュオコート エービー グルココルチコイド救急治療用の医薬組成物
SE0401031D0 (sv) 2004-04-22 2004-04-22 Duocort Ab A new glucocorticoid replacement therapy
RU2382637C2 (ru) * 2004-04-30 2010-02-27 Астеллас Фарма Инк. Фармацевтическая композиция для перорального введения в форме частиц с рассчитанным временем высвобождения и быстро распадающиеся таблетки, содержащие указанную композицию
RU2385156C2 (ru) * 2004-05-31 2010-03-27 Лабораториос Альмираль С.А. Комбинации, содержащие антимускариновые средства и кортикостероиды
US20070281007A1 (en) * 2004-08-27 2007-12-06 Jacob Jules S Mucoadhesive Oral Formulations of High Permeability, High Solubility Drugs
RU2290940C2 (ru) * 2004-10-18 2007-01-10 Государственное образовательное учреждение высшего профессионального образования "Нижегородская Государственная Медицинская академия" МЗ РФ (ГОУ ВПО НижГМА) Средство для коррекции острой почечной недостаточности при токсическом гепаторенальном синдроме, индуцированном четыреххлористым углеродом, и способ коррекции острой почечной недостаточности при токсическом гепаторенальном синдроме, индуцированном четыреххлористым углеродом
WO2007053197A2 (en) * 2005-06-03 2007-05-10 Elan Pharma International, Limited Nanoparticulate acetaminophen formulations
WO2008126076A2 (en) * 2007-04-11 2008-10-23 Perrigo Israel Pharmaceuticals Ltd. Low-dose mometasone formulations
GB0817120D0 (en) 2008-09-19 2008-10-29 Diurnal Ltd Treatment of adrenal insufficiency
NZ595428A (en) 2009-04-07 2013-04-26 Duocourt Pharma Ab Improved glucocorticoid therapy
KR20150043548A (ko) * 2009-10-01 2015-04-22 앱탈리스 파마테크, 인코포레이티드 경구 투여용 코르티코스테로이드 조성물
SG10201407965XA (en) * 2009-12-02 2015-02-27 Aptalis Pharma Ltd Fexofenadine microcapsules and compositions containing them
BR112012029466A2 (pt) 2010-05-20 2017-03-01 Duocort Phama Ab "composição de glicocorticoide, método melhorado para tratar a deficiência de glicocorticoide, e, método para dar origem a uma dosagem individualizada de glicocorticoides"
GB201119985D0 (en) * 2011-11-19 2012-01-04 Diurnal Ltd Treatment of adrenal insufficiency
GB201308933D0 (en) 2013-05-17 2013-07-03 Diurnal Ltd Paediatric composition

Similar Documents

Publication Publication Date Title
JP2014111603A5 (enExample)
JP2015205922A5 (enExample)
JP2012158592A5 (enExample)
JP2012193216A5 (enExample)
CN109415406A (zh) 羊毛甾醇前药化合物及其制备方法和应用
JP2017501848A5 (enExample)
ECSP11011289A (es) Formulaciones galénicas de compuestos orgánicos
PE20161373A1 (es) Composiciones de liberacion retardada de linaclotida
JP2012505884A5 (enExample)
UY32822A (es) Composiciones farmacéuticas para el tratamiento de cáncer y otras enfermedades o trastornos
NZ714517A (en) Delayed release cysteamine bead formulation
JP2019533651A5 (enExample)
CR20140019A (es) Procedimiento para la fabricación de una composición farmacéutica en forma de tabletas de liberación prolongada conteniendo pirfenidona y su aplicación en la regresión de la insuficiencia real crónica, contractura capsular mamaria y ...
RU2018146504A (ru) Лечение внутрипеченочных холестатических заболеваний
JOP20200064A1 (ar) تحضير صور جرعة صلبة تشتمل على أجسام مضادة بعمل طبقات من المحلول/ المعلق
JP2017507142A5 (enExample)
JP2016523250A5 (enExample)
PH12014502609A1 (en) Mutilayer coating form of orally administered pharmaceutical composition containing omega-3 fatty acid or alkyl ester thereof and statin based drug
JP2017515879A5 (enExample)
WO2012052169A3 (de) Partikelförmige pharmazeutische zusammensetzung mit einem opioid und einem opioid-antagonisten
JP2015508411A5 (enExample)
JP2014507475A5 (enExample)
HRP20201315T1 (hr) Pripravak koji sadrži hidrokortizon
PH12016500693A1 (en) Slow-release solid oral compositions
JP2015120758A5 (enExample)